:: CLDF ::

The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial

Ann Intern Med. 2021 Feb 2. doi: 10.7326/M20-0202. Online ahead of print.

Christophe Bureau¹, Dominique Thabut², Caroline Jezequel³, Isabelle Archambeaud⁴, Louis D'Alteroche⁵, Sêbastien Dharancy⁶, Patrick Borentain⁷, Frédéric Oberti⁸, Aurélie Plessier⁹, Victor De Ledinghen¹⁰, Nathalie Ganne-Carrié¹¹, Nicolas Carbonell¹², Vanessa Rousseau¹³, Agnès Sommet¹³, Jean Marie Péron¹, Jean Pierre Vinel¹

Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy

Ann Hepatol. 2021 Feb 20;100333. doi: 10.1016/j.aohep.2021.100333. Online ahead of print.

Patricia P Bloom¹, Jesús M Luévano Jr², Kelsey J Miller³, Raymond T Chung⁴

Hepatic Encephalopathy: Diagnosis and Management

J Transl Int Med. 2020 Dec 31;8(4):210-219. doi: 10.2478/jtim-2020-0034.eCollection 2020 Dec.

Lorenzo Ridola¹, Jessica Faccioli¹, Silvia Nardelli¹, Stefania Gioia¹, Oliviero Riggio¹

North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension

Clin Gastroenterol Hepatol. 2021 Jul 15;S1542-3565(21)00749-7.doi: 10.1016/j.cgh.2021.07.018. Online ahead of print.

Justin R Boike¹, Bartley G Thornburg², Sumeet K Asrani³, Michael B Fallon⁴, Brett E Fortune⁵, Manhal J Izzy⁶, Elizabeth C Verna⁷, Juan G Abraldes⁸, Andrew S Allegretti⁹, Jasmohan S Bajaj¹⁰, Scott W Biggins¹¹, Michael D Darcy¹², Maryjane A Farr¹³, Khashayar Farsad¹⁴, Guadalupe Garcia-Tsao¹⁵, Shelley A Hall¹⁶, Caroline C Jadlowiec¹⁷, Michael J Krowka¹⁸, Jeanne Laberge¹⁹, Edward W Lee²⁰, David C Mulligan²¹, Mitra K Nadim²², Patrick G Northup²³, Riad Salem², Joseph J Shatzel²⁴, Cathryn J Shaw²⁵, Douglas A Simonetto²⁶, Jonathan Susman²⁷, K Pallav Kolli¹⁹, Lisa B VanWagner²⁸, Advancing Liver Therapeutic Approaches (ALTA) Consortium

Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis

JPEN J Parenter Enteral Nutr. 2021 Jul 20. doi: 10.1002/jpen.2222. Online ahead of print.

Takao Miwa¹, Tatsunori Hanai^1 2, Kayoko Nishimura², Toshihide Maeda¹, Yui Ogiso¹, Kenji Imai¹, Atsushi Suetsugu¹, Koji Takai^1 3, Makoto Shiraki¹, Masahito Shimizu¹

Sleep and liver disease: a bidirectional relationship

Lancet Gastroenterol Hepatol. 2021 Jul 14;S2468-1253(21)00169-2.doi: 10.1016/S2468-1253(21)00169-2. Online ahead of print.

Thomas Marjot¹, David W Ray², Felicity R Williams³, Jeremy W Tomlinson², Matthew J Armstrong⁴

Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States

J Med Econ. 2021 Jan 19;1. doi: 10.1080/13696998.2021.1877148. Online ahead of print.

Michael L Volk¹, Rebecca Burne², Annie Guérin², Sherry Shi², George Joseph³, Zeev Heimanson³, Maliha Ahmad⁴

The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis

Transl Gastroenterol Hepatol. 2021 Jan 5;6:8. doi: 10.21037/tgh.2020.02.14. eCollection 2021.

Nina Kimer¹², Lise Lotte Gluud¹, Julie Steen Pedersen¹, Juliette Tavenier³, Søren Møller², Flemming Bendtsen¹

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)

BMJ Open Gastroenterol. 2020 Dec;7(1):e000531. doi: 10.1136/bmjgast-2020-000531.

K de Wit¹, J J Schaapman², F Nevens³, J Verbeek³, S Coenen⁴, F J C Cuperus⁵, M Kramer⁶, E T T L Tjwa⁷, N Mostafavi⁸, M G W Dijkgraaf⁹, O M van Delden¹⁰, U H W Beuers¹, M J Coenraad², R B Takkenberg¹¹

10.

The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis

J Hepatol. 2020 Dec 7;S0168-8278(20)33836-8. doi: 10.1016/j.jhep.2020.11.048.Online ahead of print.

Vicente Arroyo¹, Paolo Angeli², Richard Moreau³, Rajiv Jalan⁴, Joan Claria⁵, Jonel Trebicka⁶, Javier Fernández⁵, Thierry Gustot⁷, Paolo Caraceni⁸, Mauro Bernardi⁸, investigators from the EASL-CLIF Consortium, Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EFClif)

11.

Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE)

Liver Int. 2021 Jan 7. doi: 10.1111/liv.14785. Online ahead of print.

Chiara Formentin¹, Lisa Zarantonello¹, Chiara Mangini¹, Anna Chiara Frigo¹, Sara Montagnese¹, Carlo Merkel¹

12.

The use of Rifaximin in Patients with Cirrhosis

Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708. Online ahead of print.

Paolo Caraceni¹, Victor Vargas², Elsa Solà³, Carlo Alessandria⁴, Koos de Wit⁵, Jonel Trebicka⁶⁷, Paolo Angeli⁸, Rajeshwar P Mookerjee⁹, François Durand¹⁰, Elisa Pose³, Aleksander Krag¹¹¹², Jasmohan S Bajaj¹³, Ulrich Beuers⁵, Pere Ginès³

13.

Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges

J Clin Med. 2020 Nov 23;9(11):3784. doi: 10.3390/jcm9113784.

Philipp Schindler¹, Hauke Heinzow², Jonel Trebicka³, Moritz Wildgruber^1 4